68Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer

被引：32
作者：
Damjanovic, Jonathan [1 ]
Janssen, Jan-Carlo [1 ]
Prasad, Vikas [2 ]
Diederichs, Gerd [1 ]
Walter, Thula [1 ]
Brenner, Winfried [3 ]
Makowski, Marcus R. [1 ,4 ]
机构：
[1] Charite, Dept Radiol, Charitepl 1, D-10117 Berlin, Germany
[2] Univ Ulm, Dept Nucl Med, Albert Einstein Allee 23, D-89081 Ulm, Germany
[3] Charite, Dept Nucl Med, Augustenburger Pl 1, D-13353 Berlin, Germany
[4] Kings Coll London, Div Imaging Sci, London, England
来源：
CANCER IMAGING | 2019年 / 19卷 / 1期
关键词：
Liver metastasis; PSMA; PET; CT; Prostate cancer; GA-68-LABELED PSMA LIGAND; NEUROENDOCRINE DIFFERENTIATION; CLINICAL CHARACTERISTICS; RADIOLIGAND THERAPY; DIAGNOSTIC-VALUE; PET/CT; CARCINOMA; AUTOPSY;
D O I：
10.1186/s40644-019-0220-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
BackgroundThe purpose of this study was to evaluate the imaging properties of hepatic metastases in Ga-68-PSMA positron emission tomography (PET) in patients with prostate cancer (PC).Methods(68)Ga-PSMA-PET/CT scans of PC patients available in our database were evaluated retrospectively for liver metastases. Metastases were identified using Ga-68-PSMA-PET, CT, MRI and follow-up scans. Different parameters including, maximum standardized uptake values (SUVmax) of the healthy liver and liver metastases were assessed by two- and three-dimensional regions of interest (2D/3D ROI).ResultsOne hundred three liver metastases in 18 of 739 PC patients were identified. In total, 80 PSMA-positive (77.7%) and 23 PSMA-negative (22.3%) metastases were identified. The mean SUVmax of PSMA-positive liver metastases was significantly higher than that of the normal liver tissue in both 2D and 3D ROI (p0.05). The mean SUVmax of PSMA-positive metastases was 9.844.94 in 2D ROI and 10.27 +/- 5.28 in 3D ROI; the mean SUVmax of PSMA-negative metastases was 3.25 +/- 1.81 in 2D ROI and 3.40 +/- 1.78 in 3D ROI, and significantly lower than that of the normal liver tissue (p0.05). A significant (p0.05) correlation between SUVmax in PSMA-positive liver metastases and both size ((Spearman)=0.57) of metastases and PSA serum level ((Spearman)=0.60) was found.ConclusionsIn Ga-68-PSMA-PET, the majority of liver metastases highly overexpress PSMA and is therefore directly detectable. For the analysis of PET images, it has to be taken into account that also a significant portion of metastases can only be detected indirectly, as these metastases are PSMA-negative.
引用
收藏
页数：9
相关论文
共 35 条
[11]   Metastatic patterns of prostate cancer:: An autopsy study of 1,589 patients [J].
Bubendorf, L ;
Schöpfer, A ;
Wagner, U ;
Sauter, G ;
Moch, H ;
Willi, N ;
Gasser, TC ;
Mihatsch, MJ .
HUMAN PATHOLOGY, 2000, 31 (05) :578-583
[12]   Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer [J].
Dietlein, Markus ;
Kobe, Carsten ;
Kuhnert, Georg ;
Stockter, Simone ;
Fischer, Thomas ;
Schomaecker, Klaus ;
Schmidt, Matthias ;
Dietlein, Felix ;
Zlatopolskiy, Boris D. ;
Krapf, Philipp ;
Richarz, Raphael ;
Neubauer, Stephan ;
Drzezga, Alexander ;
Neumaier, Bernd .
MOLECULAR IMAGING AND BIOLOGY, 2015, 17 (04) :575-584
[13]  
Dureja S, 2017, INDIAN J NUCL MED, V32, P13, DOI 10.4103/0972-3919.198450
[14]   Novel Preclinical and Radiopharmaceutical Aspects of [Ga-68]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer [J].
Eder, Matthias ;
Neels, Oliver ;
Mueller, Miriam ;
Bauder-Wust, Ulrike ;
Remde, Yvonne ;
Schaefer, Martin ;
Hennrich, Ute ;
Eisenhut, Michael ;
Afshar-Oromieh, Ali ;
Haberkorn, Uwe ;
Kopka, Klaus .
PHARMACEUTICALS, 2014, 7 (07) :779-796
[15]   Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy [J].
Eiber, Matthias ;
Maurer, Tobias ;
Souvatzoglou, Michael ;
Beer, Ambros J. ;
Ruffani, Alexander ;
Haller, Bernhard ;
Graner, Frank-Philipp ;
Kuebler, Hubert ;
Haberhorn, Uwe ;
Eisenhut, Michael ;
Wester, Hans-Juergen ;
Gschwend, Juergen E. ;
Schwaiger, Markus .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (05) :668-674
[16]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[17]   Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy [J].
Hirano, D ;
Okada, Y ;
Minei, S ;
Takimoto, Y ;
Nemoto, N .
EUROPEAN UROLOGY, 2004, 45 (05) :586-592
[18]  
Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.21492, 10.3322/caac.20107]
[19]   Current use of PSMA - PET in prostate cancer management [J].
Maurer, Tobias ;
Eiber, Matthias ;
Schwaiger, Markus ;
Gschwend, Juergen E. .
NATURE REVIEWS UROLOGY, 2016, 13 (04) :226-235
[20]   Diagnostic Efficacy of 68Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer [J].
Maurer, Tobias ;
Gschwend, Juergen E. ;
Rauscher, Isabel ;
Souvatzoglou, Michael ;
Haller, Bernhard ;
Weirich, Gregor ;
Wester, Hans-Juergen ;
Heck, Matthias ;
Kuebler, Hubert ;
Beer, Ambros J. ;
Schwaiger, Markus ;
Eiber, Matthias .
JOURNAL OF UROLOGY, 2016, 195 (05) :1436-1442
1234